A phase II study of second-line bendamustine in relapsed or refractory small cell lung cancer (SCLC).
N. K. Venepalli
No relevant relationships to disclose
A. S. Hutchison
No relevant relationships to disclose
D. P. Carbone
No relevant relationships to disclose
D. H. Johnson
Consultant or Advisory Role - miRNA Therapeutics (U)
V. L. Keedy
No relevant relationships to disclose
W. Pao
No relevant relationships to disclose
A. Sandler
Consultant or Advisory Role - Cephalon
L. Horn
No relevant relationships to disclose